United States - English - NLM (National Library of Medicine)

kyowa kirin, inc. - istradefylline (unii: 2gz0lik7t4) (istradefylline - unii:2gz0lik7t4) - nourianz is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with parkinson's disease (pd) experiencing "off" episodes. none. risk summary there are no adequate data on the developmental risk associated with the use of nourianz in pregnant women. in animal studies (see data ), oral administration of istradefylline during pregnancy resulted in teratogenicity (increased incidences of fetal structural abnormalities, embryofetal and offspring mortality and growth deficits) at clinically relevant exposures and in the absence of maternal toxicity. the teratogenic effects of istradefylline in pregnant rabbits were substantially greater when administered in combination with levodopa/carbidopa than when administered alone. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respe

Bangladesh - English - DGDA (Directorate General of Drug Administration)

incepta pharmaceuticals ltd. - istradefylline - tablet - 20 mg

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

kyowa kirin co.,ltd - istradefylline - yellowish brown tablet, diameter 7.1 mm, thickness 3.3 mm